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Elevated Levels of Oxidative Stress Markers in Exhaled
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Paul S. Thomas, BSc (Pharm), MB, BS, MHPEd, MD, FRCP, FRACP*†
Introduction: Lung cancer is the leading cause of cancer death and
oxidative stress secondary to carcinogens such as cigarette smoke
has been implicated in its pathogenesis. Therefore, lung cancer
patients were hypothesized to have higher levels of oxidative stress
markers in their exhaled breath compared with controls.
Methods: Exhaled breath condensate (EBC) was collected from
newly diagnosed subjects with non-small cell lung cancer (NSCLC)
and control subjects in a cross-sectional observational study. The
samples were then analyzed for hydrogen peroxide (H2O2), pH,
8-isoprostane, and antioxidant capacity.
Results: A total of 71 subjects (21 NSCLC patients, 21 nonsmokers,
13 exsmokers, and 16 smokers) were recruited. NSCLC patients had
significantly higher EBC H2O2 concentration (NSCLC subjects
versus smokers, 10.28 M, 95% confidence interval CI: 4.74–
22.30 and 2.29 M, 95% CI: 1.23–4.25, respectively, p  0.003)
and lower antioxidant capacity (NSCLC versus smokers, 0.051 mM,
95% CI: 0.042–0.063 and 0.110 mM, 95% CI: 0.059–0.206, p 
0.023; NSCLC versus all controls as a group, 0.051 mM, 95% CI:
0.042–0.063 and 0.087 mM, 95% CI: 0.067–0.112, p  0.001).
They also had significantly lower pH (5.9, 3.3–7.3) compared with
exsmokers (6.7, 5.8–7, p  0.009).
Conclusion: The significant increase of H2O2 and reduction in anti-
oxidant capacity in the EBC of lung cancer patients further support the
concept of the disequilibrium between levels of oxidants and antioxi-
dants in lung cancer, which leads to increased oxidative stress. These
findings suggest oxidative stress is implicated in the development of
lung cancer and may be an early marker of the disease.
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Oxidative stress has been implicated in the pathogenesisof many respiratory conditions including lung cancer
(Figure 1). This is based on the hypothesis that the lungs are
directly exposed to higher oxygen concentrations compared
with other organs and hence more susceptible to increased
oxidative stress, either through constant exposure to oxidants
derived internally from normal metabolic processes or expo-
sure to ambient air containing environmental irritants or
pollutants such as cigarette smoke and free-radical generating
environmental carcinogens.1 Under normal physiological
conditions, there is a balance between the production of these
oxidants and removal by the body’s antioxidant system.2 The
disequilibrium between levels of oxidants and antioxidants
results in oxidative stress which has been implicated in the
multistep process of carcinogenesis, because oxidants influ-
ence apoptosis, growth, and senescence as regulated by on-
cogenes and tumor suppressor genes such as CKIp21 and
PTEN, and even to increase angiogenesis, which is a critical
pathway in the proliferation of cancer cells.3,4 This is further
supported by studies showing decreased levels of antioxi-
dants such as ascorbic acid, glutathione, and -carotene in the
plasma of lung cancer patients compared with controls5; and
increased levels of oxidants such as nitrite, nitrate, and
malondialdehyde in the plasma of lung cancer patients com-
pared with controls.5 Lung cancer subjects were hypothesized
to have higher levels of oxidative stress markers in their
exhaled breath compared with controls. The objective of this
research was to measure specific oxidative stress markers in
the exhaled breath condensate (EBC) of subjects, including
hydrogen peroxide (H2O2), a surrogate measure of airway
oxidant burden as it is soluble and equilibrates with air;
8-isoprostane, a prostaglandin analogue produced by free-
radical-initiated peroxidation of arachidonic acid; pH that
measures the levels of airway acidification; and antioxidant
capacity that gives a general measure of the antioxidant status
in the airway.6–9
PATIENTS AND METHODS
Subjects
The study was approved by the South Eastern Sydney
Area Health Service Research Ethics Committee. Subjects
were recruited from Prince of Wales Hospital. Patients with
newly diagnosed lung cancer before treatment were recruited
from the oncology clinic. The control group included subjects
without lung cancer, and no history of chronic obstructive
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pulmonary disease (COPD) or other respiratory conditions
matched for socioeconomic and age group, and comprised
nonsmokers, smokers, and exsmokers, defined as not having
smoked for at least 1 year. Informed consent was obtained
from subjects before sample collection and a questionnaire
administered to obtain demographic details including medical
history, medication, smoking history, and also staging and
histologic typing of lung cancer as appropriate. The time
since last meal, drinks (e.g., tea, coffee), or cigarette was also
recorded and EBC was obtained from subjects only after at
least 1 hour had elapsed since the consumption of food,
beverages, or cigarettes. Individuals with recent or current
infection/sepsis were not recruited in this study to prevent
confounding effect of a local or systemic inflammation.
Collection
EBC was obtained by breathing into a nonsiliconized
glass collection device, cooled by ice to 4°C as previously
validated.10 This method has been shown not to allow sali-
vary contamination as judged by an assay for salivary amy-
lase (unpublished data). Subjects breathed tidally for 10 to 15
minutes through a mouthpiece with a unidirectional valve
leading into the cooling device to collect 1 ml of EBC. The
samples were then aliquoted into Eppendorf tubes (120 l),
deaerated by argon degassing for 1 minute and agitated
before storage under argon at 80°C before analyses for pH,
H2O2, antioxidant capacity, and 8-isoprostane. The antioxi-
dant butylated hydroxytoluene (5 l of 0.13% BHT) was
added into the 8-isoprostane aliquots to act as a free-radical
scavenger before storage at 80°C.
Analysis
Reagents were obtained from Sigma-Aldrich (Sydney,
Australia) unless otherwise specified.
pH
A pH meter (Model IQ125 Professional, IQ Scientific
Instruments, San Diego, CA) was used to measure pH of the
EBC samples. Three point calibrations, using pH 4, 7, and 14
buffers, were carried out before pH measurement. EBC sam-
ples were deaerated by argon and 10 l of the samples was
added to the probe tip before reading the values directly off
from the display.
Hydrogen Peroxide
H2O2 was measured by a spectrophotometric assay
method based on oxidation of 3,3,5,5-tetramethybenzidine
by horseradish peroxidase (HRP) and H2O2. EBC samples
(100 l) were added to 420 M 3,3,5,5-tetramethybenzi-
dine (100 l) in 0.42 M potassium citrate buffer and 52.5
FIGURE 1. Schematic of oxidative stress pathway in carcinogenesis. The lungs are directly exposed to many oxidants from
both normal internal physiological activities and external sources such as cigarette smoke and pollutants. This results in the
disequilibrium between oxidants and antioxidants levels, leading to increased oxidative stress. Those oxidative stress markers
marked (*) were studied in this study. Increased oxidative stress may lead to deoxyribonucleic acid damage in normal somatic
cells, leading to mutations and hence alteration of various genes implicated in the multistep carcinogenesis process. Conse-
quently, there will also be an increase in oxidative stress because of the neoplastic process or response to it. Therefore, the
increase in levels of oxidative stress markers measured in the exhaled breath condensate of lung cancer patients may be part
of the pathogenesis of or response to neoplasia.
Journal of Thoracic Oncology • Volume 4, Number 2, February 2009 Exhaled Breath Condensate and Lung Cancer
Copyright © 2009 by the International Association for the Study of Lung Cancer 173
U/ml horseradish peroxidase (10 l). After 20 minutes at
room temperature, the mixture was acidified to pH 1 with 2 M
sulfuric acid (15 l). The product, 3,3,5,5-tetramethyl-
1,1diphenoquinone 4,4diamine, was then measured spectro-
photometrically at 450 nm. Concentration of H2O2 in EBC
samples was derived directly from a standard curve (absor-
bance against concentration of H2O2 in standards) with a
range of 0 to 100 M of H2O2. In this laboratory, the
intraassay coefficient of variation is 8.2% and the limit of
detection 0.2 M.
8-Isoprostane
8-isoprostane was measured using an enzyme immuno-
assay (Cayman, Ann Arbor, MI) according to the manufac-
turer’s instructions. The intraassay coefficient of variation
was 22.1% and the limit of detection 5 pg/ml.
Antioxidant Capacity
Antioxidant capacity was measured by a spectrophoto-
metric assay method (Cayman, Ann Arbor, MI) according to
the manufacturer’s instructions. The antioxidant capacity was
measured by the inhibiton of the reaction of metmyoglobin
with 2,2-azino-di-(3-ethylbenzthiazoline sulfonate) mea-
sured by a change in absorbance at 750 nm. The antioxidant
capacity was derived by comparing samples with Trolox
standards (a tocopherol analogue). The intraassay coefficient
of variation was 3.4% and the limit of detection 0.044 mM of
Trolox equivalents.
Statistical Analysis
H2O2, 8-isoprostane, and antioxidant capacity data
were log-transformed to the Normal distribution and data
were analyzed by parametric statistics (one-way analysis of
variance ANOVA, Bonferroni posthoc test, and indepen-
dent unpaired two-tailed t test where appropriate). All values
were expressed as geometric mean with 95% confidence
intervals (CI) unless otherwise stated. pH data did not con-
form to the Normal distribution and were analyzed using
nonparametric statistics (Kruskal-Wallis test and Mann-Whit-
ney U test where appropriate). pH values were expressed as
median, range. Statistical analyses were performed using
SPSS 14.0.
RESULTS
A total of 71 patients were recruited: 21 non-small cell
lung cancer (NSCLC) patients, 21 nonsmokers, 13 exsmok-
ers, and 16 smokers. Some patients could not complete the
entire collection process, resulting in limited number of samples
collected for analysis of all markers for these patients.
Three of the lung cancer patients, two nonsmokers and
one exsmoker were using inhaled glucocorticosteroids. Sub-
ject characteristics are summarized in Table 1.
Spirometry results were available for 14 NSCLC pa-
tients and approximately two thirds of the patients showed a
degree of airway obstruction. The mean spirometry results
were: forced vital capacity 3.16 1.03 l, forced expiratory
volume in 1 second  2.10  0.78 l and forced expiratory
volume in 1 second/forced vital capacity  65  13%.
Hydrogen Peroxide
There were significant differences in mean H2O2 con-
centrations between groups when patients with NSCLC
(10.28 M, 95% CI: 4.74–22.30) were compared with the
control groups (nonsmokers, 4.87 M, 95% CI: 3.48–6.81;
exsmokers, 5.72 M, 95% CI: 3.20–10.23; smokers, 2.29
M, 95% CI: 3.20–10.23, p  0.003, ANOVA, Figure 2).
The mean H2O2 concentration of the NSCLC patients was
significantly higher than the smokers (p  0.003, unpaired t
TABLE 1. Subject Characteristics
Control Subjects Subjects with Lung Cancer
Stage 1 (1); Stage 2 (2);
Stage 3 (9); Stage 4 (9)Nonsmoker Exsmoker Smoker
n 21 13 16 21
Male/female 11/10 3/10 12/4 17/4
Age (mean  SD) 63.3  20.4 63.9  16.1 53.0  13.4 68.1  10.5
Pack years 0 12.4 40.4 44.4
FIGURE 2. Log-transformed exhaled breath condensate
hydrogen peroxide concentration (M) in control and lung
cancer subjects. Significant differences were seen between
groups (p  0.008, analysis of variance), with mean hydro-
gen peroxide concentration of smokers significantly (p 
0.003, t test) lower than the non-small cell lung cancer pa-
tients group. Smokers also had significantly lower hydrogen
peroxide concentration compared with nonsmokers (p 
0.020, t test) and exsmokers (p  0.028, t test).
Chan et al. Journal of Thoracic Oncology • Volume 4, Number 2, February 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer174
test, Figure 2); whereas current healthy smokers also had
significantly lower H2O2 concentration compared with non-
smokers (p  0.020, unpaired t test); and exsmokers (p 
0.028, unpaired t test).
8-Isoprostane
There were significant differences in mean 8-isopros-
tane concentrations between the groups (p  0.043, ANOVA,
Figure 3). All samples had detectable levels of 8-isoprostane.
The mean 8-isoprostane levels of each group are as follow:
NSCLC, 37.9 pg/ml (95% CIL: 17.8–80.8); 28.9 pg/ml (95%
CI: 13.9–60.1); exsmokers, 116.9 pg/ml (95% CI: 39.5–
345.5); and smokers, 20.7 pg/ml (95% CI: 8.9–48.4). There
was a significant difference between smokers and exsmokers
(p  0.011, unpaired t test). There was, however, no signif-
icant difference between NSCLC and the smokers (p  0.26,
unpaired t test); the exsmokers (p  0.064, unpaired t test);
and the nonsmokers (p  0.59, unpaired t test).
Antioxidant Capacity
Subjects with an EBC antioxidant capacity below the
limit of detection of the assay kit were assigned a value
equivalent to the lower limit of detection (i.e., 0.044 mM).
NSCLC subjects had a lower mean EBC antioxidant capacity
compared with smokers (0.051 mM, 95% CI: 0.042–0.063
versus 0.110 mM, 95% CI: 0.059–0.206, p  0.023, un-
paired t test). The mean EBC antioxidant capacity of exs-
mokers and nonsmokers were 0.067 mM (95% CI: 0.034–
0.135) and 0.066 mM (95% CI: 0.040–0.107), respectively.
However, there was no significant difference between groups
(p  0.132, ANOVA).
Lung cancer subjects had significantly lower antioxi-
dant capacity when compared with the amalgamated control
groups (0.080 mM, 95% CI: 0.058–0.110, p  0.012, t test,
Figure 4).
pH
Significant differences in median EBC pH were ob-
served between groups (p  0.011, Kruskal-Wallis test,
Figure 5). The median EBC pH of lung cancer patients (5.9,
3.3–7.3) was significantly lower compared with the exsmok-
ers (6.7, 5.8–7, p  0.009, Mann-Whitney). However, the
median EBC pH of nonsmokers (6.0, 4.7–7.0, p  0.003,
Mann-Whitney); and smokers (6.0, 4.1–7.2, p  0.004,
Mann-Whitney) were also significantly lower compared with
exsmokers.
DISCUSSION
This study showed that increased levels of oxidative
stress in lung cancer were detected in the EBC of lung cancer
subjects compared with that of controls. Four oxidative stress
FIGURE 3. Log-transformed exhaled breath condensate
8-isoprostane concentration (pg/ml). Significant differences
were seen between groups (p  0.043, analysis of variance),
with significantly higher 8-isoprostane concentration in non-
smokers when compared with exsmokers (p  0.011, t test).
FIGURE 4. Log-transformed exhaled breath condensate
antioxidant capacity (M) comparing the lung cancer group
with the amalgamated control group consisting of nonsmok-
ers, exsmokers, and smokers. The lung cancer group has a
significantly lower antioxidant capacity compared with the
control group (p  0.012, t test).
FIGURE 5. Exhaled breath condensate pH. Significant
differences were observed between groups (p  0.011,
Kruskal-Wallis test). The mean pH of exsmokers were signifi-
cantly higher compared with lung cancer group (p  0.009,
Mann-Whitney); nonsmokers (p  0.003, Mann-Whitney);
and smokers (p  0.004, Mann-Whitney).
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markers, pH, 8-isoprostane, H2O2, and antioxidant capacity,
were tested with differing results.
H2O2 is formed from the conversion of superoxide
anions by superoxide dismutase and is a marker of oxidative
stress, which has been shown to be elevated in various
respiratory conditions such as asthma, COPD, bronchiectasis,
acute respiratory distress syndrome, common cold, and aller-
gic rhinitis.11–15 In this study, we demonstrated that there
were significant differences between groups, with the lung
cancer group having significantly higher mean H2O2 concen-
tration when compared with the smokers. This finding has not
been described previously. It is further supported by the
finding that there was a significantly lower EBC antioxidant
capacity in lung cancer patients compared with smokers and
the amalgamated control group. This pair of novel findings
lends further support to the theory that the disequilibrium
between levels of oxidants and antioxidants results in oxida-
tive stress which is implicated in the multistep process of
carcinogenesis. The next step would be to further identify the
specific types of antioxidants. Several enzymes are associated
with H2O2 degradation, such as catalase and gluthatione-
associated enzymes,16 and it will be of interest to determine
which of these enzymes are actually down-regulated/up-
regulated so as to elucidate the pathways that are altered
during carcinogenesis.
A perhaps unexpected finding was that smokers had the
lowest H2O2 concentration and highest antioxidant capacity
compared with the other groups. It was hypothesized that
smokers would have higher levels of H2O2 compared with
nonsmokers and exsmokers as smokers are exposed to sig-
nificant quantities of reactive oxygen species in both gas and
tar phase of cigarette smoke.16 Furthermore, smokers have
been shown to have higher total white blood cells counts,
specifically with increase in neutrophils and these neutrophils
in turn have higher levels of myeloperoxidase, which would
then cause an increase in H2O2 production.17 This finding is
in contrast to a previous study by Nowak et al.,18 where
smoking subjects were found to have higher levels of H2O2
compared with nonsmoking subjects. Smoking subjects in
this study, however, have an approximately 20 pack-years
longer smoking history and the mean age of the subjects of
this study is approximately 20 years older than those in the
study by Novak et al., which may have contributed to the
difference in results, and it might have been expected that
these smokers should have even higher levels of H2O2 given
the greater exposure to the oxidative insult from cigarette
smoking. Current understanding is that free radicals in ciga-
rette smoke activate inflammatory cells with recruitment of
neutrophils and macrophages into the airway, which in turn
generate high levels of reactive oxygen and nitrogen species
and other toxic metabolites.16 The recruitment of these in-
flammatory cells may nevertheless increase antioxidant ca-
pacity at the particular site by bringing along with them
antioxidant enzymes contained within these inflammatory
cells and with some of these (e.g., gluthatione) being released
for the protection of the extracellular milieu.16 Furthermore,
superoxide dismutase and catalase activities have been shown
to be increased in human alveolar macrophages in chronic
smokers, and gluthatione-associated enzymes and manganese
superoxide dismutase induced by cigarette smoke.19,20 Hack-
ett et al.21 have also demonstrated that 16 of 44 antioxidant-
related genes were increased in the epithelium of smokers
compared with nonsmokers. The results suggest that smoking
may increase the antioxidant capacity of the airway so as to
counterbalance the influx of oxidants from the cigarette
smoke, potentially contributing to the significant decrease in
H2O2 concentration when compared with healthy controls
and lung cancer patients. This suggestion that chronic expo-
sure to oxidants resulting in increased antioxidant gene ex-
pression before the antioxidant system being overwhelmed by
oxidative stress as disease progresses is supported by the
finding that healthy smokers have the highest levels of glu-
tathione in bronchoalveolar lavage, followed by COPD pa-
tients and then COPD patients during an acute exacerbation.22
In addition, functional polymorphisms of many antioxidant
enzymes impact on enzyme activity and localization.16 For
example, in extracellular superoxide dismutase (ECSOD), a
single nucleotide substitution resulted in a 10-fold increase in
circulating ECSOD activity and a decrease in tissue binding
of ECSOD, with reports suggesting that this particular poly-
morphism may be a risk factor for developing chronic lung
disease.23 Some functional variants of antioxidant enzymes,
such as the gluthatione S-transferase P1 GG variant, are
associated with an increased risk of lung cancer,24 and it may
be worthwhile performing a comparative study of more
antioxidant enzymes and their functional polymorphisms in
the various populations (e.g., smokers, exsmokers, lung can-
cer patients) so as to determine whether they are risk factors
for the development of lung cancer or whether they confer
protection against the development of neoplasia.
The pH of EBC is a measure of airway acidification and
can be affected in disease processes such as acute asthma, cystic
fibrosis, COPD, bronchiectasis, and acute lung injury, where
hydrogen ion concentrations were found to be elevated.7,25,26 As
such, we postulated that pH of the EBC of lung cancer
patients should be lower compared with the healthy controls.
Although our results demonstrated significant differences
between groups, the median pH of the lung cancer group was
similar to the other groups except for the exsmokers. The
exsmokers have significantly higher pH compared with the
lung cancer patients, nonsmokers, and smokers. One expla-
nation for the marked elevation of pH in exsmokers may be
that the exsmokers were hyperventilating, resulting in the
accumulation of bicarbonates in the EBC. However, this
explanation may not be valid as all EBC samples were
deaerated before storage and analysis. Therefore, carbon
dioxide should have been driven out of the EBC samples and
such a problem should not have occurred. Furthermore,
subjects were told to breathe normally, and none of the
subjects were observed to be hyperventilating. We observed
that the pH values in this study were slightly lower when
compared with other studies, which could be attributed to the
differences in the degassing time. Nevertheless, it would be
expected the class difference to remain and given that pH of
lung cancer subjects is not significantly different from the
other healthy controls, this may suggest that airway acidifi-
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cation is not implicated in the pathogenesis of lung cancer
and its associated neoplastic processes.
8-isoprostane is a marker of lipid peroxidation, which
has been shown to be elevated in the EBC of patients with
chronic obstructive pulmonary disease but not in those with
asthma.27,28 Our study showed significant differences in the
concentration of 8-isoprostane between groups, with higher
levels of 8-isoprostane in the EBC of lung cancer patients
compared with that of the smokers. Khyshiktyev et al.29 have
reported, without stating the actual marker, that levels of lipid
peroxidation were lower in EBC of patients with lung cancer
compared with controls, thereby making the association of
lung cancer with increased lipid peroxidation measured in
EBC a contentious subject. This is in contrast with several
studies that have suggested that lipid peroxidation is impli-
cated in pulmonary carcinogenesis with various products of
lipid peroxidation (e.g., malondialdehyde, thiobarbituric acid-
reactive substances, lipid hydroperoxide) shown to be ele-
vated in the urine and tumors of lung cancer patients.30,31
Further research is required to determine the relationship
between the presence of various products of lipid peroxida-
tion in the airways and the pathogenesis of lung cancer.
In this study, exsmokers had fewer pack years com-
pared with smokers, but this is not surprising as age-matched
current smokers would be expected to have a higher expo-
sure. These variables could be adjusted for in a larger study
by multivariate analysis, which could not be performed in this
study. Although both control smokers and exsmokers had on
average fewer pack-years of smoking compared with lung
cancer patients, this difference was not significant and sug-
gests that the observed differences in EBC markers are not
related to differences in smoking history.
There are limitations in this study of EBC. Some of the
samples were below the limit of detection of the antioxidant
assay. Therefore, concentrating the EBC samples before anal-
ysis, or siliconising the glass collection device, may actually
increase the yield of antioxidant capacity of some EBC
markers as Liu et al.10 and Rosias et al.32 have previously
reported that collection devices significantly affect the levels
of biomarkers obtained in EBC. This may have contributed to
this study having higher levels of EBC H2O2 when compared
with other studies which have collected EBC with the Eco-
Screen (Erich Jaeger GmbH, Hochberg, Germany), but the
latter can contaminate EBC with exogenous NOx.10
Although all subjects were recruited before treatment
(e.g., radiation or chemotherapy), most of the lung cancer
patients had more advanced disease at presentation (i.e., stage
III–IV). Thus, our results may not be directly applicable to
the use of EBC analysis as a screening tool for early detection
of lung cancer in the high-risk population, and further re-
search is necessary.
Future studies could include increasing the sample size
to allow for analysis of lung cancer histopathology subtypes
and effect of stage of disease. This will allow more specific
biomarkers to be targeted for each type of lung cancer. The
effect of treatment (i.e., chemotherapy or radiotherapy) on
patients’ EBC could also be studied and used in tandem with
other measures such as tumor size on computed tomography
scan to assess response to treatment.
In conclusion, this study has shown significant differ-
ences in levels of H2O2 and antioxidant capacity between
lung cancer subjects and other control groups. EBC may
therefore be a novel method of sampling the lung to study
markers involved in the pathogenesis of lung cancer and the
role of oxidants and antioxidants.
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